Price
No data yet.
Social Signal Score
Analyst Ratings
7 analystsRevenue
$395.0KAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Paul Arthur LaViolette
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Employees
- 116
- Beta
- 1.64
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 107.62
Financials
Revenue
$395.0K-31.2%Net Income
$-23.05MEBITDA
$-22.79MFree Cash Flow
$-15.41MEPS (diluted)
$-0.32Shares Outstanding (diluted)
71.93M+440.2%Operating Expenses
$24.50MCash & Debt
$189.19MReturn of Capital
$0.00Revenue by Segment (annual)
$140.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $350.0K | $-72.78M | $-1.08 |
| 2024 | $0.00 | $-53.59M | $-0.92 |
| 2023 | $0.00 | $-42.21M | $-0.88 |
| 2022 | $700.0K | $-58.51M | $-1.72 |
| 2021 | $1.42M | $-63.66M | $-2.28 |
| 2020 | $0.00 | $-49.74M | $-2.14 |
| 2019 | $0.00 | $-45.99M | $-2.22 |
| 2018 | $0.00 | $-37.55M | $-2.20 |
| 2017 | $0.00 | $-25.57M | $-1.73 |
| 2016 | $0.00 | $-9.52M | $-0.86 |
| 2015 | $0.00 | $-2.81M | $-0.37 |
| 2014 | $0.00 | $-474.9K | $-0.19 |
Valuation
PLSEhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
77+9.52%Social Signal Score
Mentions (6)
- Newszacks.com·4d ago·Positive
All You Need to Know About Pulse Biosciences (PLSE) Rating Upgrade to Buy Pulse Biosciences (PLSE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
View source ↗ - Newsprnewswire.com·13d ago·Neutral
LG Energy Solution Wins CES Innovation Awards 2027 for Its Fast and Precise Second-Life Battery Diagnostic System /PRNewswire/ -- LG Energy Solution (KRX: 373220) today announced that Re.Pulse, its software-based state-of-health (SoH) diagnostic solution for used
View source ↗ - Newsmarketbeat.com·16d ago·Positive
What Pulse Biosciences (PLSE) Said on Its Q3 Earnings Call Pulse Biosciences NASDAQ: PLSE said it completed enrollment ahead of schedule in the pivotal U.S. study of its nPulse Cardiac Catheter, setting up a data readout expected in the third quarter of 2027 as the company increases spending on clinical development and launch preparations.
View source ↗ - Newsseekingalpha.com·16d ago·Positive
Pulse Biosciences, Inc. (PLSE) Q3 2026 Earnings Call Transcript Pulse Biosciences, Inc. (PLSE) Q3 2026 Earnings Call Transcript
View source ↗ - Newsfool.com·74d ago·Positive
Why Pulse Biosciences Stock Popped Today An analyst initiated coverage with an unambiguous buy recommendation. He feels that one market in particular is ripe for disruption by the company.
View source ↗ - Newsmarketbeat.com·98d ago·Neutral
Pulse Biosciences Eyes AFib Breakthrough With Nanosecond PFA Platform Pulse Biosciences NASDAQ: PLSE is positioning its nanosecond pulsed field ablation technology as a potential next-generation treatment platform for atrial fibrillation and other conditions, President, CEO and Co-Chairman Paul LaViolette said during the Canaccord Genuity 46th Annual Global Growth Conference.
View source ↗
Earnings
Thu, Feb 18(in 3 months)
Consensus estimate $-0.33 per share
Typical surprise -0.8% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$-0.32 vs $-0.31miss
- Thu, Aug 6$-0.36 vs $-0.31miss
- Mon, May 4$-0.27 vs $-0.32beat
- Thu, Feb 19$-0.26 vs $-0.27beat
- Wed, Nov 5$-0.29 vs $-0.31beat
- Tue, Aug 12$-0.28 vs $-0.26miss
Estimates and results for PLSE via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PLSE officers and directors.
- Bought
- $31.5m
- Sold
- $6.6m
14 trades
18 trades
- Teplitsky Liane Raebought
- Teplitsky Liane Raebought
- Teplitsky Liane Raebought
- Teplitsky Liane Raebought
- Duggan Robert Wbought
- Laviolette Paul Abought
- Laviolette Paul Abought
- Duggan Robert Wbought
68 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in PLSE.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
